Generate Biomedicines Inc (NASDAQ:GENB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Generate Biomedicines Inc (NASDAQ:GENB) has received an average rating of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $25.40.

Several research analysts have recently weighed in on GENB shares. Guggenheim started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 target price for the company. Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Piper Sandler started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 target price for the company. Morgan Stanley upped their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

Generate Biomedicines Stock Down 4.5%

GENB opened at $12.42 on Wednesday. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $16.75. The stock’s 50 day simple moving average is $12.94.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.